Table 2.
Distribution of locations among patients with recurrence and secondary urothelial carcinomas within 2 yr after open (ORC) and robot-assisted radical cystectomy (RARC)
| Variable | ORC | RARC |
|---|---|---|
| Any recurrence a | 33/79 (42) | 57/158 (36) |
| Local recurrence a | 15/65 (23) | 24/136 (18) |
| Cystectomy bed | 11 (73) | 14 (58) |
| PLND template | 6 (40) | 12 (50) |
| Distant recurrence a | 26/73 (36) | 43/147 (29) |
| Lung | 9 (35) | 14 (33) |
| Liver | 9 (35) | 10 (23) |
| Bone | 12 (46) | 16 (37) |
| Extrapelvic lymph node | 4 (15) | 10 (23) |
| Peritoneal carcinomatosis | 2 (8) | 9 (21) |
| Other (brain, adrenal) | 3 (12) | 0 |
| Secondary urothelial carcinoma | 0 | 4 |
| Upper urinary tract | 0 | 3 (75) |
| Urethra | 0 | 1 (25) |
PLND = pelvic lymph node dissection.
Data are presented as n/N (%) or n (%). Percentages for recurrence locations do not sum because four patients had local recurrences located in both the cystectomy bed and the PLND template, and 22 patients had multiple distant recurrence locations.
a
For descriptive purposes, percentages were calculated as: number of patients with event within 2 yr/(number of patients with event within 2 yr + number of patients without event and follow-up ≥2 yr).